Ann: Clinical Progress on IHL-216A for TBI and CTE, page-18

You can see that Cannavalate are backing IHL and with successful trials it will be to the exclusion of other plays.
Contacts in the US,Canada and Europe.
FDA fast track negotiations and key management who have a track record with major companies.

Cannvalate and Dr Sud have incentives at 14c and 20c.So we have a DR leading the trials with these strong incentives in play.

Also worth remembering that Cannvalate are backed by a rich lister and have already raised funds for a delayed IPO for the ASX and Canada.Can you join the dots.